EPISODE · Apr 1, 2022 · 24 MIN
Let's Talk Medtech: Why Embecta Stands Out in Diabetes Care
from Let’s Talk Medtech
Embecta is now fully independent from Becton Dickinson & Co. Devdatt Kurdikar, Embecta's CEO talks about what that means going forward and his plans for the company. With its rich pedigree and newly-independent status, Embecta is truly the new/old kid on the block in diabetes care.
Embed this episode
Ready to play
Let's Talk Medtech: Why Embecta Stands Out in Diabetes Care
0:00
24:04
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Let’s Talk Medtech?
This episode is 24 minutes long.
When was this Let’s Talk Medtech episode published?
This episode was published on April 1, 2022.
Can I download this Let’s Talk Medtech episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!